Table 1.
Baseline characteristics
| Variable | Elderly (n=5,829) | Non-elderly (n=9,357) | P-value | |
|---|---|---|---|---|
| Demographic variables | ||||
| Age (year) | 72.0 (68.0-77.0) | 54.0 (49.0-59.0) | <0.001 | |
| Male | 4,155 (71.3) | 7,879 (84.2) | <0.001 | |
| Diabetes, misssing=191 | 2,003 (34.8) | 1,934 (21.0) | <0.001 | |
| Hypertension, missing=205 | 3,016 (52.4) | 2,199 (23.8) | <0.001 | |
| Smoking, missing=200 | 1,914 (33.2) | 4,824 (52.3) | <0.001 | |
| Etiology | <0.001 | |||
| Hepatitis B virus* | 1,971 (33.8) | 7,094 (75.8) | ||
| Hepatitis C virus | 1,031 (17.7) | 535 (5.7) | ||
| Alcohol | 1,056 (18.1) | 811 (8.7) | ||
| Others | 1,771 (30.4) | 97 (9.8) | ||
| Laboratory variables | ||||
| Serum albumin, missing=392 (g/dL) | 3.7 (3.2-4.1) | 3.9 (3.3-4.3) | <0.001 | |
| Total bilirubin, missing=374 (mg/dL) | 0.9 (0.6-1.4) | 1.0 (0.7-1.6) | <0.001 | |
| INR, missing=642 | 1.10 (1.03-1.20) | 1.11 (1.04-1.22) | 0.002 | |
| Alanine aminotransferase, missing=359 (IU/L) | 31 (20-52) | 39 (25-62) | <0.001 | |
| Platelet count, missing=488 (×109/L) | 146 (100-206) | 143 (98-197) | <0.001 | |
| Creatinine, missing=458 (mg/dL) | 0.90 (0.75-1.10) | 0.86 (0.71-1.00) | <0.001 | |
| MELD score, missing=1,109 | 9.0 (7.0-11.0) | 8.0 (7.0-11.0) | 0.015 | |
| Child-Pugh class, missing=767 | <0.001 | |||
| A | 4,025 (72.5) | 6,480 (72.3) | ||
| B | 1,299 (23.4) | 1,968 (22.2) | ||
| C | 229 (4.1) | 490 (5.5) | ||
| Tumor variables | ||||
| Alpha-fetoprotein, missing=1,302 (ng/mL) | 22.1 (5.0-340.0) | 47.8 (6.9-957.0) | <0.001 | |
| Tumor number, missing=72 | <0.001 | |||
| 1 | 3,598 (62.0) | 5,677 (61.0) | ||
| 2 | 877 (15.2) | 1,219 (13.2) | ||
| 3 | 251 (4.3) | 337 (3.6) | ||
| 4 | 95 (1.6) | 120 (1.3) | ||
| ≥5 | 984 (16.9) | 1,956 (21.0) | ||
| Maximal tumor diameter, missing=1,670 (cm) | 3.5 (2.0-6.4) | 3.0 (1.9-6.0) | <0.001 | |
| Modified UICC stage, missing=115 | <0.001 | |||
| Stage I | 777 (13.4) | 1,496 (16.1) | ||
| Stage II | 2,314 (40.0) | 3,328 (35.9) | ||
| Stage III | 1,620 (28.0) | 2,232 (24.0) | ||
| Stage IV-A | 573 (9.9) | 1,215 (13.1) | ||
| Stage IV-B | 504 (8.7) | 1,012 (10.9) | ||
| BCLC stage, missing=531 | <0.001 | |||
| 0 | 582 (10.0) | 1,096 (11.7) | ||
| A | 2,283 (39.2) | 3,318 (35.5) | ||
| B | 829 (14.2) | 1,009 (10.8) | ||
| C | 908 (15.6) | 1,797 (19.2) | ||
| D | 934 (16.0) | 1,606 (17.2) | ||
Values are presented as median (interquartile range) or number (%).
INR, international normalized ratio; MELD, model for end stage liver disease; UICC, Union for International Cancer Control; BCLC, Barcelona Clinic Liver Cancer.
*
Patients co-infected with hepatitis B virus and hepatitis C virus (n=178) were also included.